**Core Concept:** Tardive dyskinesia is a movement disorder characterized by involuntary, repetitive, and often rhythmic muscle contractions, primarily affecting the face, jaw, and tongue. It is a side effect of chronic exposure to neuroleptic drugs, particularly antipsychotics.

**Why the Correct Answer is Right:**

The correct answer, Dopamine Receptor Blockers (DRBs), works by blocking dopamine receptors, which are involved in movement control and regulation. Tardive dyskinesia is a result of excess dopamine in the brain's basal ganglia, causing abnormal neuronal activity and muscle contractions. DRBs, such as haloperidol and fluphenazine, effectively reduce dopamine levels and alleviate the symptoms of tardive dyskinesia by blocking dopamine D2 receptors.

**Why Each Wrong Option is Incorrect:**

A. Antidepressants (Selective Serotonin Reuptake Inhibitors, Tricyclic Antidepressants, etc.) are generally ineffective in treating tardive dyskinesia because they primarily target serotonin and noradrenaline neurotransmitters, rather than dopamine.

B. Benzodiazepines (anxiolytics) primarily target gamma-aminobutyric acid (GABA) receptors and are not involved in dopamine regulation, making them unsuitable for treating tardive dyskinesia.

C. Antiparkinsonism agents (Levodopa, Carbidopa) are primarily used in Parkinson's disease, which is a different condition than tardive dyskinesia. Although they help in improving motor symptoms, they are not specific to tardive dyskinesia and do not address the dopamine imbalance that causes tardive dyskinesia.

Dopamine Receptor Blockers (DRBs) are the correct answer because they specifically target dopamine neurotransmission, normalize the excess dopamine levels in the basal ganglia, and improve the symptoms of tardive dyskinesia.

**Clinical Pearl:** Tardive dyskinesia is a side effect of long-term neuroleptic treatment, so it is crucial for physicians to monitor patients for this potential complication when prescribing antipsychotic medications. Early intervention with DRBs can prevent or reduce the severity of tardive dyskinesia symptoms.